Metagenomi Therapeutics, Inc. Common Stock
MGXStock
$1.24−37.98%52W
Market Cap$48.56M
P/E—
Div yield—
Beta1.62
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-37.79%
Price vs S&P 500 (4W)12.56%
VGM Score47.11
Market Capitalization$48.56M
Earnings Surprise History
Q1 26-0.61est. -0.53
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MGXMetagenomi Therapeutics, Inc. Common Stock | A | F | C | $1.24 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Metagenomi Therapeutics is a genetic medicines company developing in vivo gene editing therapies using its proprietary metagenomics-derived platform. The company's pipeline targets hemophilia A, refractory hypertension, and cardiovascular diseases. Its comprehensive editing toolbox includes programmable nucleases, base editors, and CRISPR-associated transposases, with the company also pursuing technology licensing for ex vivo cell therapy applications.